Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer

A. Ravaud* and M. Sire

首页> 外文期刊>Annals of Oncology >Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer

【24h】

Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer

机译：动脉高血压和舒尼替尼，索拉非尼和贝伐单抗在转移性肾细胞癌的一线和二线治疗中的临床获益

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Annals of Oncology》 |2009年第5期|p.966-967|共2页
作者
A. Ravaud* and M. Sire;
展开▼
作者单位

Department of Medical Oncology, Hopital Saint-Andre, CHU de Bordeaux, Bordeaux Cedex, France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer [J] . A. Ravaud amp, M. Sire Annals of oncology: official journal of the European Society for Medical Oncology . 2009,第5期

机译：动脉高血压和舒尼替尼，索拉非尼和贝伐单抗在转移性肾细胞癌的一线和二线治疗中的临床获益
2. Reply to Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer [J] . P. Bono* and H. Joensuu Annals of Oncology . 2009,第5期

机译：答复动脉高血压和舒尼替尼，索拉非尼和贝伐单抗在转移性肾细胞癌的一线和二线治疗中的临床益处
3. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer [J] . Eichelberg Christian, Vervenne Walter L., De Santis Maria, European urology . 2015,第5期

机译：开关：一项随机，连续，开放标签的研究，以评估索拉非尼-舒尼替尼与舒尼替尼-索拉非尼治疗转移性肾细胞癌的疗效和安全性
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. Cost-Benefit Analysis of Nanoparticle Albumin-Bound Paclitaxel versus Solvent-Based Paclitaxel for the Treatment of Metastatic Breast Cancer in the United States [D] . Vichansavakul, Kittaya 2013

机译：纳米白蛋白结合紫杉醇与溶剂型紫杉醇在美国治疗转移性乳腺癌的成本效益分析
6. Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma [O] . Thomas E. Hutson, Bernard Escudier, Emilio Esteban, -1

机译：替莫罗莫司与索拉非尼的III期随机试验作为舒尼替尼治疗转移性肾细胞癌患者的二线治疗
7. PCN5 PHARMACOECONOMIC ANALYSIS OF SORAFENIB AND SUNITINIB FOR FIRST LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) COMPARED WITH COMBINATION THERAPY OF BEVACIZUMAB, GEMCITABINE, AND CAPECITABINE (BGC) AT A LARGE CANCER CENTER [O] . Smith WD, Arbuckle R 2007

机译：索拉非尼和舒尼替尼用于一线治疗转移性肾细胞癌（MRCC）与贝伐单抗，吉西他滨和卡培他滨（BGC）联合治疗在大型癌症中心的一线治疗的PCN5药物经济学分析

Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer

著录项

相似文献

相关主题

期刊订阅